Predictive Oncology (POAI) stock price, revenue, and financials

Predictive Oncology market cap is $15.2 m, and annual revenue was $1.41 m in FY 2019
View Company

$15.2 M

POAI Mkt cap, 23-Sept-2020

$182.8 K

Predictive Oncology Revenue Q2, 2020
Predictive Oncology Gross profit (Q2, 2020)97.5 K
Predictive Oncology Gross profit margin (Q2, 2020), %53.4%
Predictive Oncology Net income (Q2, 2020)-3.6 M
Predictive Oncology EBIT (Q2, 2020)-3.8 M
Predictive Oncology Cash, 30-Jun-20203.4 M
Predictive Oncology EV17.8 M

Predictive Oncology Revenue

Predictive Oncology revenue was $1.41 m in FY, 2019

Embed Graph

Predictive Oncology Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

96.6k188.8k468.1k951.6k654.4k456.5k654.8k1.4m1.4m

Revenue growth, %

103%(31%)

Cost of goods sold

56.1k128.5k189.7k385.3k304.0k181.6k148.0k415.8k531.8k

Gross profit

40.6k60.2k278.4k566.2k350.4k274.9k506.8k995.9k879.8k

Gross profit Margin, %

42%32%59%60%54%60%77%71%62%

Sales and marketing expense

232.7k173.0k578.8k1.2m504.0k468.0k1.0m2.4m1.9m

R&D expense

15.0k406.0k289.0k

General and administrative expense

3.6m6.3m7.5m4.9m3.4m5.2m6.0m4.6m9.8m

Operating expense total

3.8m6.5m8.1m6.1m3.9m6.0m7.3m7.0m14.7m

EBIT

(13.8m)

EBIT margin, %

(976%)

Interest expense

230.4k259.3k636.5k377.7k390.9k3.0

Interest income

510.3k287.1k

Investment income

(2.3m)(439.6k)

Income tax expense

Net Income

(4.5m)(7.4m)(9.4m)(6.8m)(4.8m)(6.5m)(7.7m)(10.1m)(19.4m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

2.4k20.3k22.6k25.0k51.6k127.7k107.8k70.2k318.3k397.3k151.3k234.0k85.8k96.9k85.4k134.6k175.2k106.8k152.5k411.6k358.6k329.9k255.2k286.2k522.7k294.9k182.8k

Cost of goods sold

1.8k11.2k13.8k1.7k70.0k41.6k26.2k31.1k98.4k134.7k96.0k83.6k19.8k85.9k36.8k26.5k37.0k22.0k28.7k117.3k109.0k83.0k73.7k118.4k208.1k92.7k85.3k

Gross profit

554.09.1k8.8k23.3k(18.3k)86.1k81.7k39.1k219.9k262.5k55.3k150.4k66.0k11.0k48.7k108.1k138.2k84.8k123.8k294.3k249.6k246.9k181.5k167.8k314.6k202.3k97.5k

Gross profit Margin, %

23%45%39%93%(36%)67%76%56%69%66%37%64%77%11%57%80%79%79%81%71%70%75%71%59%60%69%53%

Sales and marketing expense

68.5k61.0k31.9k29.2k13.5k84.0k164.7k204.9k319.3k325.1k234.0k139.0k66.7k108.4k102.6k137.8k147.5k231.3k301.7k550.5k554.1k621.5k554.2k685.0k435.0k264.4k133.0k

R&D expense

4.8k58.3k

General and administrative expense

272.9k428.8k565.7k2.0m2.5m1.8m3.2m1.2m1.3m737.5k127.8k856.2k861.1k1.7m2.3m733.1k1.1m2.2m621.7k1.2m729.5k762.6k1.5m3.3m2.6m2.8m3.2m

Operating expense total

341.4k489.8k597.6k2.0m2.5m2.0m3.4m1.4m1.6m1.1m361.8k995.2k927.8k1.8m2.4m870.9k1.3m2.4m923.4k1.8m1.3m1.4m2.1m5.3m3.8m3.6m3.9m

EBIT

(5.1m)(3.4m)(3.4m)(3.8m)

EBIT margin, %

(1782%)(659%)(1166%)(2062%)

Interest expense

57.9k61.0k55.5k89.3k23.7k95.6k407.5k18.1k14.8k131.9k153.6k189.2k51.8k3.0

Interest income

53.4k15.1k27.1k

Investment income

(960.5k)(645.8k)

Income tax expense

Net Income

(387.4k)(654.1k)(713.4k)(2.1m)(2.9m)(2.1m)(4.0m)(1.6m)(1.7m)(1.1m)(225.8k)(1.2m)(1.1m)(2.2m)(2.6m)(1.1m)(1.3m)(2.5m)(992.1k)(1.8m)(2.4m)(2.5m)(3.3m)1.5m(4.0m)(4.5m)(3.6m)

Predictive Oncology Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

123.0k13.1k102.0k16.4k4.9m1.8m766.2k162.2k150.8k

Accounts Receivable

50.3k39.7k97.2k57.5k38.3k38.9k137.5k232.6k297.1k

Prepaid Expenses

30.1k27.4k60.6k190.0k271.6k290.0k318.4k160.2k

Inventories

97.6k145.2k122.2k367.4k231.7k272.2k265.0k241.1k190.2k

Current Assets

301.0k225.5k382.0k631.3k5.4m2.6m2.4m1.5m798.3k

PP&E

4.6k3.5k158.1k196.5k139.6k87.7k180.5k1.5m

Goodwill

15.7m

Total Assets

446.2k369.6k593.4k901.0k5.6m2.8m3.6m3.7m22.4m

Accounts Payable

731.1k733.6k1.1m2.2m650.4k220.1k140.5k445.7k3.2m

Short-term debt

471.6k280.0k937.4k307.0k5.3m

Current Liabilities

2.4m3.4m3.5m6.2m1.5m1.6m932.3k3.7m10.9m

Long-term debt

630.2k89.3k1.0m

Total Debt

630.2k560.9k280.0k937.4k307.0k6.3m

Total Liabilities

3.8m6.4m1.5m1.9m932.3k3.7m11.1m

Common Stock

320.7k1.0m2.2m30.9k52.1k69.4k140.9k40.6k

Preferred Stock

206.0

Additional Paid-in Capital

8.8m14.9m23.3m30.1m44.5m(47.9m)57.4m63.0m93.7m

Retained Earnings

(40.5m)47.0m(54.8m)(63.1m)(82.5m)

Total Equity

(2.7m)(3.3m)(3.2m)(5.5m)4.1m923.7k2.7m53.5k11.2m

Debt to Equity Ratio

-0.2 x-0.2 x-0.1 x-0.2 x5.7 x

Debt to Assets Ratio

1.4 x1.5 x0.5 x1 x0.1 x

Financial Leverage

-0.2 x-0.1 x-0.2 x-0.2 x1.4 x3 x1.3 x69.4 x2 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

57.6k77.7k22.4k35.3k102.1k372.9k137.1k328.4k130.7k40.2k244.0k44.1k7.7m1.5m583.0k634.5k2.1m1.2m765.7k2.2m1.0m209.9k1.1m69.6k98.6k3.1m3.4m

Accounts Receivable

792.019.3k19.1k32.1k39.8k96.7k101.9k83.2k63.9k149.6k238.6k15.9k14.2k52.8k23.6k68.5k45.0k91.7k241.8k315.3k238.6k173.4k299.0k372.1k269.8k272.5k

Prepaid Expenses

45.0k30.6k62.3k66.3k23.0k56.0k35.6k34.5k122.6k149.5k149.0k202.6k213.2k170.9k221.2k163.2k160.3k188.5k196.8k208.3k275.5k404.4k265.6k154.5k131.6k262.5k426.7k

Inventories

91.9k96.8k134.4k141.4k108.0k101.1k391.6k360.7k315.6k257.7k236.9k256.5k292.2k289.2k249.2k242.2k238.9k272.6k244.7k278.2k289.0k320.9k210.4k155.7k235.4k

Current Assets

103.4k127.7k195.7k230.4k299.4k667.0k382.6k547.1k708.8k700.0k947.2k520.2k8.2m3.8m2.7m1.7m5.3m4.3m3.3m3.1m2.0m3.1m3.7m1.1m1.1m3.7m4.3m

PP&E

5.6k5.0k4.5k4.1k3.8k3.2k12.5k37.5k221.1k204.7k216.9k147.2k126.6k137.6k121.5k110.9k112.7k109.9k100.0k106.0k184.4k198.3k148.7k1.8m1.6m1.4m2.4m

Goodwill

23.8m23.8m15.7m15.7m

Total Assets

250.6k274.2k340.7k375.1k443.8k810.8k443.6k636.6k997.5k972.8k1.2m745.5k8.4m4.1m2.9m1.9m5.5m4.5m3.5m6.0m4.0m5.4m5.1m32.3m31.9m25.0m27.5m

Accounts Payable

731.9k720.0k728.3k663.5k723.4k612.2k661.1k636.1k1.1m1.6m1.6m2.5m1.1m791.7k750.5k648.1k79.3k57.4k74.6k186.3k165.6k409.1k432.2k3.5m3.8m3.1m2.4m

Short-term debt

608.8k598.8k378.6k978.8k81.1k1.2m933.1k1.3m4.2m4.9m

Current Liabilities

1.9m2.0m2.6m2.4m2.5m3.0m3.4m1.4m2.3m3.9m4.8m6.9m2.6m1.5m1.6m1.5m1.3m1.3m1.2m4.8m9.5m10.8m12.4m14.7m

Long-term debt

660.2k705.6k546.6k89.3k89.3k255.1k504.1k386.0k2.3m1.1m

Total Debt

660.2k705.6k546.6k698.1k688.1k378.6k978.8k81.1k1.2m933.1k1.5m504.1k386.0k6.6m5.9m

Total Liabilities

1.8m2.7m4.2m5.1m6.9m2.6m1.5m2.1m1.9m1.5m1.3m1.2m783.6k639.3k2.4m5.0m10.0m11.2m14.7m15.8m

Common Stock

235.8k291.4k386.4k673.2k986.0k1.2m1.2m2.2m2.2m2.2m30.0k33.1k5.2m532.6k777.0k34.0k64.9k61.9k62.3k118.0k120.9k134.0k173.6k309.7k31.5k58.5k131.9k

Preferred Stock

206.0206.0

Additional Paid-in Capital

5.6m6.1m9.2m11.8m14.4m17.3m17.9m23.1m26.5m26.6m29.4m30.9m44.7m45.2m46.3m52.3m54.0m54.1m61.6m62.1m64.3m66.3m86.9m89.6m97.3m102.2m

Retained Earnings

(42.7m)(45.2m)(46.3m)(48.4m)(50.9m)(51.9m)(56.5m)(58.9m)(61.4m)(66.4m)(64.9m)(68.9m)(87.0m)(90.6m)

Total Equity

(2.4m)(2.5m)(3.0m)(2.3m)(2.2m)(2.8m)(3.5m)(1.2m)(1.7m)(3.2m)(3.8m)(6.1m)5.8m2.5m785.2k11.5k4.0m3.2m2.3m5.2m3.4m3.0m70.0k22.3m20.7m10.4m11.7m

Debt to Equity Ratio

-0.3 x-0.3 x-0.2 x-0.3 x-0.3 x-0.1 x-0.3 x0 x-0.3 x-0.2 x21.7 x0 x

Debt to Assets Ratio

2.6 x2.6 x1.6 x1.9 x1.6 x0.5 x2.2 x0.1 x0.9 x1.3 x0.3 x0 x

Financial Leverage

-0.1 x-0.1 x-0.1 x-0.2 x-0.2 x-0.3 x-0.1 x-0.5 x-0.6 x-0.3 x-0.3 x-0.1 x1.4 x1.6 x3.7 x166.5 x1.4 x1.4 x1.5 x1.2 x1.2 x1.8 x72.7 x1.4 x1.5 x2.4 x2.4 x

Predictive Oncology Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(4.5m)(7.4m)(9.4m)(6.8m)(4.8m)(6.5m)(7.7m)(10.1m)(19.4m)

Depreciation and Amortization

3.2k1.1k148.8k63.0k78.6k82.4k71.6k147.6k704.9k

Accounts Receivable

(50.3k)10.6k(57.5k)39.7k19.3k(636.0)(98.6k)(95.1k)143.3k

Inventories

(97.6k)(47.6k)23.0k(245.2k)135.6k(40.5k)7.2k24.0k91.1k

Accounts Payable

71.7k421.1k429.0k1.1m(1.5m)(430.3k)(79.6k)305.2k365.8k

Cash From Operating Activities

(1.8m)(1.2m)(3.9m)(3.4m)(7.5m)(4.4m)(4.5m)(5.3m)(8.7m)

Purchases of PP&E

(162.8k)(101.4k)(32.5k)(32.8k)(45.1k)(177.7k)(5.9k)

Cash From Investing Activities

(216.1k)(121.2k)(60.6k)(422.9k)(1.7m)(1.1m)(599.1k)

Long-term Borrowings

(16.3k)(305.0k)(1.2m)

Cash From Financing Activities

1.9m1.1m4.2m3.4m12.4m1.7m5.1m5.8m9.3m

Net Change in Cash

113.6k(109.8k)88.8k(85.6k)4.8m(3.1m)(997.9k)(604.0k)(11.3k)

Interest Paid

31.0k146.1k

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(864.8k)(1.5m)(713.4k)(2.8b)(5.7m)(2.1m)(3.3m)(7.3m)(1.6m)(3.4m)(4.5m)(225.8k)(1.4m)(2.5m)(2.2m)(4.7m)(5.8m)(1.3m)(3.9m)(4.9m)(1.8m)(4.1m)(6.6m)(3.3m)(1.8m)(5.8m)(4.5m)(8.1m)

Depreciation and Amortization

1.2k1.8k147.0457.0768.0311.0141.5k156.4k9.4k25.8k44.1k19.9k39.0k57.5k21.0k42.1k62.4k18.6k36.0k53.8k18.2k41.1k105.6k39.5k259.4k483.6k206.6k402.7k

Accounts Receivable

(792.0)(19.3k)31.2k18.2k10.5k(57.0k)(62.2k)(43.5k)33.4k(52.4k)(141.4k)(32.5k)41.7k43.4k(14.5k)14.7k(6.7k)(29.6k)(6.1k)(52.8k)(104.3k)(177.8k)(101.1k)59.2k141.3k68.3k27.3k113.8k

Inventories

5.7k813.0(36.8k)3.8k37.2k44.1k(269.4k)(238.5k)(193.4k)66.0k109.7k130.5k(24.8k)(60.4k)(57.5k)23.0k30.0k33.3k(7.5k)20.4k(13.1k)(48.0k)(55.7k)60.6k34.5k(45.2k)

Accounts Payable

52.4k40.6k(2.8k)177.2k387.3k(77.8k)(29.0k)3.0k40.5k563.2k515.7k269.6k279.7k(1.1m)141.3k100.1k(2.4k)(140.8k)(162.7k)(145.5k)45.8k25.1k268.6k(13.5k)718.5k942.2k(27.1k)(614.7k)

Cash From Operating Activities

(807.8k)(1.2m)(250.2k)(644.1k)(780.7k)(940.3k)(2.1m)(3.3m)(1.8m)(1.9m)(3.1m)(5.2k)(214.6k)(4.6m)(1.6m)(2.8m)(3.7m)(1.2m)(2.1m)(3.1m)(1.7m)(3.1m)(4.1m)(2.0m)(4.0m)(5.9m)(3.0m)(6.7m)

Purchases of PP&E

(9.8k)(49.8k)(72.4k)(72.4k)(103.0k)(17.4k)(18.7k)(25.1k)(26.9k)(38.6k)(43.3k)(32.8k)(130.0k)(170.0k)(855.0)

Cash From Investing Activities

(58.4k)(101.9k)(86.6k)(87.2k)(122.3k)(7.7k)(7.7k)(23.7k)(1.8m)(1.6m)(603.7k)(2.3m)(2.3m)(1.7m)145.6k44.9k(96.2k)(624.7k)(580.9k)(591.8k)(32.5k)90.0k

Long-term Borrowings

(7.5k)(10.3k)(300.0k)(300.0k)(305.0k)(93.8k)(220.2k)(609.5k)(821.9k)(1.5m)

Cash From Financing Activities

856.0k1.3m149.7k556.4k759.9k1.3m2.3m3.8m1.9m2.0m3.4m250.0k12.4m86.3k86.3k86.3k3.8m3.8m3.8m3.0m3.3m3.6m3.6m4.5m6.5m5.9m9.9m

Net Change in Cash

48.3k68.3k(100.6k)(87.7k)(20.8k)359.7k123.9k315.2k28.8k(61.8k)142.1k(12.9k)27.7k7.7m(3.3m)(4.3m)322.3k(604.2k)(998.4k)1.5m238.1k(556.3k)962.6k(92.6k)(63.6k)2.9m3.2m

Interest Paid

26.4k26.2k

Predictive Oncology Ratios

USDQ2, 2011

Debt/Equity

-0.3 x

Debt/Assets

2.6 x

Financial Leverage

-0.1 x
View Predictive Oncology profile

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more